EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Patients With Relapsed Large B‐Cell Lymphoma After 12 Months Have a Similarly Poor Prognosis to Those Relapsing Within 12 Months

Hilde T van der Galiën iD, Hilde A M Kooistra, Robby Kibbelaar, Nic J G M Veeger, Marcel Nijland, Gerwin Huls, Tom van Meerten, Rozemarijn S van Rijn, Hemobase Population Registry Consortium

European Journal of Haematology · 2025

DOI: 10.1111/ejh.70003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, 2025. Verfasst von Hilde T van der Galiën und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Frisius MC, Leeuwarden, the Netherlands. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Servier.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor T‐cell therapy (CART) has replaced salvage immunochemotherapy followed by high‐dose chemotherapy and autologous stem cell transplantation (HDT‐ASCT) as the preferred second‐line treatment for early relapsed (< 12 months) large B‐cell lymphoma (LBCL). However, for patients with a late relapse (> 12 months), CART is inaccessible until third line. We analyzed 877 patients from the HemoBase registry (diagnosed 2005–2020) to assess differences in long‐term outcomes of early versus late relapse in second line. Early relapse occurred in 120/654 patients (18%) who completed first‐line treatment, with 2‐ and 5‐year overall survival (OS) of 22% and 18%. Late relapse occurred in 70 patients (11%), showing slightly better 2‐year OS of 36% but similarly poor 5‐year OS of 20%. Only 13% of early and 16% of late relapsed patients completed HDT‐ASCT, achieving 5‐year OS of 71% and 49%, respectively. Most patients initiating salvage immunochemotherapy did not reach HDT‐ASCT and had dismal survival (5‐year OS 8% early, 18% late), comparable to HDT‐ASCT‐ineligible patients (10% early, 14% late). These real‐world data highlight poor outcomes with previous second‐line therapies and support alternative strategies like CART in second line for patients with both early relapsing (< 12 months) and late relapsing (> 12 months) LBCL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseHumansMaleFemaleMiddle AgedPrognosisAgedRecurrenceAdultSalvage TherapyImmunotherapy, AdoptiveTime FactorsRegistriesTreatment OutcomeHematopoietic Stem Cell TransplantationCombined Modality TherapyYoung AdultTransplantation, Autologous

Stichwörter der Autor:innen

long term survivalmarrow/stem cell transplantation—clinical results in lymphomanon‐Hodgkin lymphomareal‐world evidencetreatment of relapse

Autor:innen und Institutionen

  • Department of Hematology, Frisius MC, Leeuwarden, the Netherlands.
  • Department of Hematology, University Medical Center Groningen, Groningen, the Netherlands.
  • Pathology Friesland, Leeuwarden, the Netherlands.
  • Frisus MC Academy, Frisius MC, Leeuwarden, the Netherlands.
  • Department of Epidemiology, University Medical Center Groningen, the Netherlands.

ORCID-Profile: Hilde T van der Galiën

Förderung

  • Servier

Zitieren

APA

van der Galiën, H. T., Kooistra, H. A. M., Kibbelaar, R., Veeger, N. J. G. M., Nijland, M., Huls, G., van Meerten, T., van Rijn, R. S., & Hemobase Population Registry Consortium (2025). Patients With Relapsed Large B‐Cell Lymphoma After 12 Months Have a Similarly Poor Prognosis to Those Relapsing Within 12 Months. European Journal of Haematology. https://doi.org/10.1111/ejh.70003

Vancouver

van der Galiën HT, Kooistra HAM, Kibbelaar R, Veeger NJGM, Nijland M, Huls G, et al. Patients With Relapsed Large B‐Cell Lymphoma After 12 Months Have a Similarly Poor Prognosis to Those Relapsing Within 12 Months. European Journal of Haematology. 2025. doi:10.1111/ejh.70003

BibTeX
@article{vanderGalin2025,
  author = {van der Galiën, Hilde T and Kooistra, Hilde A M and Kibbelaar, Robby and Veeger, Nic J G M and Nijland, Marcel and Huls, Gerwin and van Meerten, Tom and van Rijn, Rozemarijn S and Hemobase Population Registry Consortium, Hemobase Population Registry Consortium},
  title = {Patients With Relapsed Large B‐Cell Lymphoma After 12 Months Have a Similarly Poor Prognosis to Those Relapsing Within 12 Months},
  journal = {European Journal of Haematology},
  year = {2025},
  doi = {10.1111/ejh.70003}
}
Kostenlos starten →